Group items matching

in title, tags, annotations or url

Metastatic osteosarcoma is one form of the disease osteoarthritis. It has been found that this disease occurs due to a problem with the cells in the spinal cord that are responsible for the proper function of the joints. The disease generally affects the aging group and those individuals suffering from other medical conditions like diabetes etc. The pain caused due to metastatic osteosarcoma can be so severe that it leads to tremendous disability to the affected person. Increasing drug pipeline for malignant bones and soft tissue cancer is expected to drive growth of the global metastatic osteosarcoma treatment market. Key biopharmaceutical and pharmaceutical companies are focused on research and development activities to synthesize novel drug treatment for soft tissue and malignant bone cancer. For instance, in September 2020, Junshi Biosciences, a major biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/metastatic-osteosarcoma-treatment.html

Focal Segmental Glomerulosclerosis is presently considered as a set of clinical syndromes sharing a very similar common histopathologic lesion namely, focal scarring in the glomerulus followed by fibrosis, fibrous nodules, and fibric infiltrate. Although various causes may be involved in the pathogenesis of this condition, the most common mechanoreceptor sites of action are the interneurons in the optic nerve and the choroid. The choroid can be damaged due to injuries or diseases like leukemia, lymphoma, myelodysplasia, and so on. Since these choroid sites contain many cell types, a wide variety of cell-damage mechanisms have been proposed to underlie Focal Segmental Glomerulosclerosis. Focal Segmental Glomerulosclerosis is also known as nephrotic syndrome and can be effectively addressed through surgical and non-surgical treatment options. The increasing prevalence of focal segmental glomerulosclerosis is expected to drive growth of the global focal segmental glomerulosclerosis market during the forecast period. According to the National Organization for Rare Disorders (NORD), in the U.S., focal segmental glomerulosclerosis is expected to affect around 7 people per million people in the general population. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/focal-segmental-glomerulosclerosis.html

Gouty arthritis is a type of arthritis that causes inflammation, typically in one joint, which begins suddenly. Gouty arthritis is caused by the deposition of needle-shaped crystals of uric acid in a joint. The primary symptoms of gouty arthritis include severe pain, swelling, and redness in joints, often in the big toe. Increasing prevalence of gout with rising alcohol consumption is expected to drive growth of the global gouty arthritis market. According to the Centers for Disease Control and Prevention (CDC), from 2013-2015 around 54.4 million adults in the U.S. have some form of arthritis, gout, rheumatoid arthritis, or fibromyalgia. According to the Arthritis Foundation, 8 million people in the U.S. suffer from gout arthritis every year. According to the same source, high intake of sugary or alcoholic drinks is one of the major risk factors for gout arthritis. Alcohol is a major source of purine, which produces uric acid. High levels of uric acids in the body can result in the formation of crystals of uric acid, eventually leading to gout. Hence, such factors are expected to drugs market is expected to drive growth of the global gouty arthritis market. Furthermore, increasing adoption of biologics and increasing R&D activities in regenerative medicines is expected to propel the global gouty arthritis market growth in the near future. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/gouty-arthritis-market-is-gaining.html